IOVA vs. TWST, RLAY, FATE, CBPO, NKTR, QGEN, PCVX, RVMD, RGEN, and HALO
Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Twist Bioscience (TWST), Relay Therapeutics (RLAY), Fate Therapeutics (FATE), China Biologic Products (CBPO), Nektar Therapeutics (NKTR), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector.
Iovance Biotherapeutics (NASDAQ:IOVA) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. 10.4% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 3.9% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Twist Bioscience has higher revenue and earnings than Iovance Biotherapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics presently has a consensus target price of $24.45, indicating a potential upside of 164.37%. Twist Bioscience has a consensus target price of $49.75, indicating a potential downside of 14.34%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Twist Bioscience.
Iovance Biotherapeutics received 469 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.54% of users gave Iovance Biotherapeutics an outperform vote while only 57.76% of users gave Twist Bioscience an outperform vote.
Twist Bioscience has a net margin of -69.24% compared to Iovance Biotherapeutics' net margin of -23,615.70%. Twist Bioscience's return on equity of -31.61% beat Iovance Biotherapeutics' return on equity.
Iovance Biotherapeutics has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.
In the previous week, Twist Bioscience had 3 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 14 mentions for Twist Bioscience and 11 mentions for Iovance Biotherapeutics. Twist Bioscience's average media sentiment score of 0.49 beat Iovance Biotherapeutics' score of 0.37 indicating that Twist Bioscience is being referred to more favorably in the news media.
Summary
Iovance Biotherapeutics beats Twist Bioscience on 9 of the 17 factors compared between the two stocks.
Get Iovance Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iovance Biotherapeutics Competitors List
Related Companies and Tools
